Ecolab Inc. (NYSE:ECL) pre-announced its Q4 results, with earnings coming in worse than expected and full 2022-year guidance being 11% below Street estimates.

The lower-than-expected Q4 earnings (9% below Street) was because of higher raw material costs and costs to expedite product to customers in the face of COVID and supply chain disruptions. As a result, the company made a decision to increase prices by 12% for all Life Sciences division offerings, effective February 1.